| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2864106 | The American Journal of the Medical Sciences | 2010 | 4 Pages |
Abstract
Fixed-dose capecitabine and oxaliplatin combination on an every-other-week schedule showed activity in refractory SCCHN. The simplicity and toxicity profile of this regimen compares favorably with other commonly used chemotherapies and should be tested in larger studies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Guilherme MD, Leela MD, Donald M. MD, PhD, Goetz H. MD, Damian A. MD, FACP,